To include your compound in the COVID-19 Resource Center, submit it here.

Evoke's Gimoti shows bioequivalence to Reglan in PK trial

Evoke Pharma Inc. (NASDAQ:EVOK) reported top-line data from a pharmacokinetic trial showing that 2 of 3 doses of Gimoti (EVK-001) achieved bioequivalence based on

Read the full 242 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE